Skip to content
Programming Cell Therapies to Overcome Solid Tumor Defense Systems episode artwork

Sep 16, 2021 28 min

Programming Cell Therapies to Overcome Solid Tumor Defense Systems

from The Bio Report Hosted by Levine Media Group

While CAR-T cell therapies have emerged as promising anti-cancer agents, their success have been focused on hematologic cancers. ArsenalBio is working to develop more robust cell therapies capable to treating a broader range of cancers by using synthetic biology to make them programable. We spoke to Ken Drazen, CEO of ArsenalBio, about the company’s next-generation T cell therapies, how it is able to program functions into these cells to overcome solid tumor defenses, and the company’s collaboration with Bristol-Myers Squibb announced at the start of the year.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Programming Cell Therapies to Overcome Solid Tumor Defense Systems

0:00 28:28

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 28 minutes long.

When was this The Bio Report episode published?

This episode was published on September 16, 2021.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.